Division of Cardiovascular Medicine, Temple University Hospital, Philadelphia, PA 19140, USA.
Transl Res. 2010 Jan;155(1):10-9. doi: 10.1016/j.trsl.2009.06.009.
Stem cells (SCs) possess the ability to differentiate into cells of various tissues. Although the differentiation of SCs into functional cardiomyocytes has been difficult to demonstrate in humans, clinical trials using SCs in the setting of acute myocardial infarction (AMI) have demonstrated variable results. Interpretation of these trials has been difficult because of multiple variables, which include differences in trial design, cell type, timing of cell delivery, and outcome measurements. Herein, a summary of all clinical trials in subgroups of direct injection, indirect mobilization, and combination approaches of SC therapy in AMI is provided with significant findings in each group.
干细胞 (SCs) 具有分化为各种组织细胞的能力。尽管在人类中很难证明SCs 分化为功能性心肌细胞，但在急性心肌梗死 (AMI) 中使用SCs 的临床试验已经取得了不同的结果。由于多个变量，包括试验设计、细胞类型、细胞输送时间和结果测量的差异，这些试验的解释变得困难。本文提供了 AMI 中直接注射、间接动员和SCs 治疗联合方法亚组的所有临床试验的总结，并在每组中列出了重要发现。
